Sagimet Biosciences

A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the

Weekly injectable drugs are seen as future market leaders in metabolic dysfunction-associated steatohepatitis (MASH), but there may be room for oral drugs to treat the liver disease, and analysts have

The number of biopharma initial public offerings in the US in 2024 grew to four with IPOs by Alto Neuroscience Inc. and Fractyl Health , showing that investors continue to be supportive of certain

Sagimet Biosciences hopes to bring its fatty acid synthase (FASN) inhibitor denifanstat into Phase III development for non-alcoholic steatohepatitis (NASH) during the second half of 2024 after a Phas